EP1761785B1 - Verfahren zur diagnose von lawsonia intracellularis - Google Patents

Verfahren zur diagnose von lawsonia intracellularis Download PDF

Info

Publication number
EP1761785B1
EP1761785B1 EP05755345A EP05755345A EP1761785B1 EP 1761785 B1 EP1761785 B1 EP 1761785B1 EP 05755345 A EP05755345 A EP 05755345A EP 05755345 A EP05755345 A EP 05755345A EP 1761785 B1 EP1761785 B1 EP 1761785B1
Authority
EP
European Patent Office
Prior art keywords
intracellularis
elisa
cells
antibody
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05755345A
Other languages
English (en)
French (fr)
Other versions
EP1761785A1 (de
Inventor
Malik Merza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04014804A external-priority patent/EP1609870A1/de
Application filed by Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica GmbH
Priority to PL05755345T priority Critical patent/PL1761785T3/pl
Priority to EP05755345A priority patent/EP1761785B1/de
Priority to SI200531153T priority patent/SI1761785T1/sl
Publication of EP1761785A1 publication Critical patent/EP1761785A1/de
Application granted granted Critical
Publication of EP1761785B1 publication Critical patent/EP1761785B1/de
Priority to CY20101101071T priority patent/CY1110948T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the present invention relates to the field of animal health and in particular to Lawsonia intracellularis.
  • the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies.
  • the invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.
  • L. intracellularis the causative agent of porcine proliferative enteropathy ("PPE"), affects virtually all animals, including humans, rabbits, ferrets, hamsters, fox, horses, and other animals as diverse as ostriches and emus.
  • PPE porcine proliferative enteropathy
  • a consistent feature of PPE is the occurrence of intracytoplasmic, non-membrane bound curved bacilli within enterocytes in affected portions of intestine.
  • the bacteria associated with PPE have been referred to as " Campylobacter-like organisms.”
  • the causative bacteria have been identified as a novel taxonomic genus and species, vernacularly referred to as Ileal symbiont (IS) intracellularis.
  • Ileal symbiont Ileal symbiont
  • L. intracellularis is an obligate, intracellular bacterium which cannot be cultured by normal bacteriological methods on conventional cell-free media and has been thought to require attached epithelial cells for growth.
  • S. McOrist et al., Infection and Immunity, Vol. 61, No. 19, 4286-4292 (1993 ) and G. Lawson et al., J. of Clinical Microbiology, Vol. 31, No. 5, 1136-1142 (1993 ) discuss cultivation of L. intracellularis using IEC-18 rat intestinal epithelial cell monolayers in conventional tissue culture flasks.
  • H. Stills, Infection and Immunity, Vol. 59, No. 9, 3227-3236 (1991 ) discusses using Intestine 407 human embryonic intestinal cell monolayers and GPC-16 guinea pig colonic adenocarcinoma cell monolayers in conventional tissue culture flasks.
  • L. intracellularis can be cultivated be methods known in the art, preferably, according to United States Patent Nos. 5,714,375 and 5,885,823 .
  • culture cells may first be inoculated with an inoculum comprising L. intracellularis bacteria so as to infect the cells with the bacteria.
  • Numerous cell lines can be used in practicing the invention, including, but not limited to, IEC-18 (ATCC 1589)-rat intestinal epithelial cells, HEp-2 (ATCC 23)-human epidermoid carcinoma cells, McCoys (ATCC 1696)-mouse (non-specified) cells, BGMK (Biowhittaker #71-176)-buffalo green monkey kidney cells, and swine intestinal epithelium cells.
  • the preferred culture cells are HEp-2, McCoys or IEC-18 cells.
  • the cells may be in the form of a monolayer.
  • the cells may be seed into conventional flasks. Each flask is generally seeded with between about 1x10 5 cells to about 10x10 5 cells per 25, 75, 150, 850 cm 2 flask or roller bottle mixed with growth media.
  • the growth media may be any media for cel cultivation which includes a nitrogen source, necessary growth factors for the chosen culture cells, and a carbon source, such as glucose or lactose.
  • the preferred media is DMEM fortified with Ham's F 12 with 1-5% fetal bovine serum, although other commercially available media may be used with good results.
  • the culture cell monolayer should be at about 20 percent to about 50 percent confluency at the time of inoculation.
  • the cells should be at about 30 percent to about 40 percent confluency at the time of inoculation, most preferably at about 30 percent confluency.
  • the cells prior to being inoculated, may be grown in suspension, as described infra.
  • the cells are first grown to 100% confluency in the form of a monolayer in an adherent type system, e.g., a roller bottle system, and then transferred to 3-3000 liters and grown in suspension.
  • the inoculum may be a culture of L. intracellularis obtained from infected swine or other animals.
  • the inoculum can be an intestinal homogenate prepared by scraping the mucosa off of the ileum of a swine or other animal infected with PPE.
  • ileal sections selected for culture should show severe lesions with gross thickening of the gut. Due to the fragile nature of the bacteria, samples should preferably be stored at -70°C as quickly as possible after necropsy.
  • An antibiotic to which L. intracellularis is resistant such as Vancomycin, Amphotericin B or members of the aminoglycoside group of antibiotics, including Gentamicin and Neomycin, to name a few, is preferably added to the inoculum to suppress contaminating bacteria while permitting L. intracellularis growth.
  • inoculation of the culture cells can be performed by various techniques known in the art, given the teachings herein.
  • the bacteria and/or inoculated culture cells are then incubated under a reduced dissolved O 2 concentration.
  • dissolved oxygen concentrations greater than 10% L. intracellularis growth is less than optimal with cessation of growth eventually occurring at oxygen concentrations outside this range.
  • the bacteria and/or inoculated culture cells are incubated in a dissolved oxygen concentration in the range of about 0% to about 10%. More preferably, the bacteria and/or cells are incubated in an oxygen concentration in the range of about 0% to about 8%, with an oxygen concentration of about 0% to about 3.0% being most preferred.
  • the proper concentration of carbon dioxide is also important to the proper growth of L. intracellularis. At carbon dioxide concentrations greater than 0% and less than 4%, non-optimum growth occurs with cessation of growth eventually occurring at carbon dioxide concentrations outside this range. Preferably, the carbon dioxide concentration is in the range from about 6% to about 10%, with a carbon dioxide concentration of about 8.8% being most preferred.
  • the cells are preferably incubated at a hydrogen concentration in the range from about 73% to about 96%. Nitrogen may be used in place of some or all of the hydrogen present. Most preferably, the cells are incubated in about 0 to about 8.0% O 2 , about 8.8% CO 2 , and about 83.2% H 2 .
  • Inoculated cells may be incubated in a dual gas incubator or other gas chambers which contains the proper hydrogen, oxygen and carbon dioxide concentrations and which allows the cells to be suspended during incubation.
  • the chamber should comprise a means for maintaining the inoculated cells in suspension, and a gas monitor and supply source to supply and maintain the proper gas concentrations.
  • the incubation temperature should be in the range of from 30°C to about 45°C and is more preferably in the range of from about 36°C to about 38°C. Most preferably, the temperature is about 37°C.
  • the necessary equipment for cultivation and attenuation is readily available to those or ordinary skill in the art given the teachings herein.
  • One example of equipment suitable for carrying out the resent invention is a dual gas incubator, e.g., model 480 (Lab-Line, Melrose Park, IL) in conjunction with spinner flasks to maintain the cells in suspension.
  • the presently preferred equipment comprises a fermentor, bioreactor, stir plate or rotary shaker containing media and capable of maintaining the culture cells in suspension via sparging gas of the appropriate concentration, or other means of mechanical agitation, and continuously monitoring dissolved O 2 levels in the media. New Brunswick, Braun and other companies make suitable fermentors and bioreactors for this purpose.
  • the culture cells can be agitated and maintained in suspension by a variety of methods known in the art including, for example, culture flasks, roller bottles, membrane cultures, biobags, WAVETM bioreactor systems, and spinner flasks.
  • the cells may be kept in suspension during incubation by incubating the cells in a spinner flask inside a dual gas incubator or similar apparatus.
  • spinner flask as used herein, means a flask or other container which employs a paddles, propeller or other means to agitate the culture and keep the cells contained therein in suspension.
  • the inoculated cells are incubated until the cells reach confluency and then the cells are placed in a spinner flask containing growth media and incubated in a dual gas incubator while spinning the flask.
  • the inoculated cells are scraped or trypsinized and passaged into the spinner flask. This can be achieved by a variety of methods known in the art such as using a cell scraper to detach the cells.
  • the paddle of the spinner flask is typically rotated in the range of from about 30 to about 60 rpm on a magnetic stir plate in order to maintain the infected cells in suspension.
  • a portion of the cultivated L. intracellularis is then passaged to fresh culture to increase the production of L. intracellularis bacteria.
  • the term "passaging” or variations thereof herein means the process of transferring a portion of the cultivated L. intracellularis to fresh culture cells in order to infect the fresh cells with the bacterium.
  • fresh means cells which have not yet been infected by L. intracellularis. Preferably such cells are on the average no more than approximately one day old.
  • the passage of L. intracellularis in suspension cultures may be accomplished by removing a portion of the original culture and adding it to a new flask containing fresh culture cells. If the original culture has a high number of bacteria/ml, for example, greater than about 10 4 bacteria/ml, it is preferable to add between about 1 to 10% (volume to volume) of culture from the infected flask to a new flask containing fresh cells. This is preferably done when 50-100% of the cells are infected. If fewer than 50% of the cells are infected, passaging is preferably accomplished by splitting the culture 1:2 into a new flask and scaling-up the volume by adding fresh media. In either case, cell lysis and other steps are not required, in direct contrast to the passage of monolayer cultures, as in the prior art.
  • the L. intracellularis bacteria is harvested by centrifuging the contents of all or a portion of the suspension to pellet the culture cells, resuspending the resulting cell pellets, and lysing the infected cells. Typically, at least a portion of the contents is centrifuged at about 3000xg for about 20 minutes in order to pellet the cells and bacteria.
  • the pellet may then be resuspended in, for example, a sucrose-phosphate-glutamate (SPG) solution and passed approximately 20 times through a 25 gauge needle in order to lyse the cells.
  • SPG sucrose-phosphate-glutamate
  • the samples can be centrifuged at about 145xg for about five minutes to remove cellular nuclei and debris.
  • the supernatant may then be centrifuged at about 3000xg for about twenty minutes and the resulting pellet resuspended in an appropriate diluent, such as SPG with fetal bovine serum (to prepare harvested bacteria suitable for lyophilization, freezing, or use as an inoculant) or growth media (to prepare harvested bacteria more suitable for passaging to fresh cells).
  • an appropriate diluent such as SPG with fetal bovine serum (to prepare harvested bacteria suitable for lyophilization, freezing, or use as an inoculant) or growth media (to prepare harvested bacteria more suitable for passaging to fresh cells).
  • McCoys or IEC-18 cells it is preferable to add gelatin, agarose, collagen, acrylamide or silica beads, such as Cultisphere-G porous microcarriers (HyClone Laboratories, Logan Utah), along with the growth media.
  • HEp-2 cells and others do not require microcarriers according to the methods used herein.
  • HEp-2 cultures For culture maintenance purposes, with HEp-2 cultures, preferably 25% to 50% of the culture is removed and replaced with fresh media at weekly intervals. For cell cultures with microcarriers or beads, preferably 25% to 50% of the culture is removed and replaced with fresh media 1-2 times weekly. For scale-up purposes, an additional 25% to 50% of media, or media with microcarriers, may be added to the culture.
  • passage to fresh cells generally occurs between about every 2 to about 7 days. Assuming that the culture cells become at least 70% infected within 2 to 7 days, preferably passage occurs between about every 5 to 7 days.
  • Diagnosis of L. intracellularis antigen is carried out today by using direct immuno-fluorescence and PCR. Diagnosis of antibodies specific to L. intracellularis is carried out today by using immuno-fluorescence. These methods are laborious and time consuming and are not suitable for large scale screenings.
  • the technical problem underlying the present invention is to provide improved methods for diagnosis of L. intracellularis disease.
  • the present invention relates to the field of animal health and in particular to Lawsonia intracellularis.
  • Disclosed is a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies.
  • the invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.
  • L. intracellularis means the intracellular, curved gram-negative bacteria described in detail by C. Gebhart et al., Int'l. J. of Systemic Bacteriology, Vol. 43, No. 3, 533-538 (1993 ) and S. McOrist et al., Int'l. J. of Systemic Bacteriology, Vol. 45, No. 4, 820-825 (1995 ), which are the causative bacteria which can be obtained from PPE infected swine or other animals throughout the world given the knowledge in the art and the teachings herein; and variants or mutants of any of the above bacteria, whether spontaneously or artificially obtained and DNA, RNA and bacterial proteins specific for L. intracellularis, including proteins expressed in vectors or after in vivo application, and also fragments or antigenic derivatives of L. intracellularis. This term also includes adapted isolates and attenuated isolates as defined below.
  • the term 'adapted isolate' means any L. intracellularis isolate that is prepared according to the cultivation and passaging techniques in cell culture or any other technique to replicate L. intracellularis for purposes of antigen preparation.
  • the term "attenuated isolate” means any L. intracellularis isolate that is prepared according to the cultivation and passaging techniques taught herein to achieve avirulence while maintaining immunogenic properties when administered to a host animal.
  • the term "large-scale cultivation” means a level of cultivation of L. intracellularis greater than approximately 2.0 to 3.0 liters and includes production on a scale of 100 liters or more.
  • “Cultivation” as used herein, means the process of promoting the growth, reproduction and/or proliferation of L. intracellularis.
  • the aim of the present invention is to provide a method of diagnosing pre-clinical or clinical L. intracellularis infection. Furthermore, an immune response to L. intracellularis shall be detected and a tool for L. intracellularis epidemiology is to be provided.
  • Such antibodies include any antibody type known to the skilled person, in particular immunoglobulins of the subtypes IgA, souble IgA, IgM, IgG (IgG1, IgG2a, IgG2b, IgG3), and also IgD, IgE.
  • the method is based on the fact that
  • L. intracellularis also includes fragments or antigenic derivatives of L. intracellularis, which may be used in a method as above.
  • the liquid sample may include any bodily fluid including saliva, sweat, urine, blood, secretions, excretions or other bodily fluid samples known to the expert in the field.
  • the liquid sample is collected using either a collection container (for urine or other liquid), a syringe/collection tube (for blood) or some type of collection swab (for saliva, sweat etc.)
  • a collection container for urine or other liquid
  • a syringe/collection tube for blood
  • some type of collection swab for saliva, sweat etc.
  • step c) is carried out as above.
  • the method is an immune test.
  • An immune test uses monoclonal antibodies or polyclonal antisera specific to L. intracellularis.
  • Immune tests according to the invention include the methods of detection known in the art such as the ELISA test (enzyme-linked immuno-sorbent assay) or the so-called sandwich-ELISA test, dot blots, immunoblots, radioimmuno tests (radioimmunoassay RIA), diffusion-based Ouchterlony test or rocket immunofluorescent assays.
  • Other immune tests are the indirect or direct immunofluorescent antibody test ("IFA").
  • Another immune test is the so-called Western blot (also known as Western transfer procedure or Western blotting).
  • Western blot The purpose of Western blot is to transfer proteins or polypeptides separated by polyacrylamide gel electrophoresis onto a nitrocellulose filter or other suitable carrier and at the same time retain the relative positions of the proteins or polypeptides obtained from the gel electrophoresis. The Western blot is then incubated with an antibody which specifically binds to the protein or polypeptide under consideration. These methods of detection can be used by the average skilled person to perform the invention described herein.
  • the invention further relates to a diagnostic test kit for detecting L. intracellularis infection which contains all the elements required to carry out a method of diagnosing pre-clinical or clinical L. intracellularis infection as described herein.
  • the invention further relates, in particular, to a diagnostic test kit which contains antibodies specific to L. intracellularis.
  • the invention further relates, in particular, to a diagnostic test kit, characterised in that the antibodies according to the invention are polyclonal.
  • the invention further relates, in particular to a diagnostic test kit, characterised in that the antibodies according to the invention are monoclonal.
  • a diagnostic test kit is a collection of all the components for a method of diagnosis according to the invention. Some examples (not an exhaustive list) of other elements for performing a process according to the invention include containers such as 96-well plates or microtitre plates, test tubes, other suitable containers, surfaces and substrates, membranes such as nitrocellulose filter, washing reagents and buffers.
  • a diagnostic test kit may also contain reagents which may detect bound antibodies, such as for example labelled secondary antibodies, chromophores, enzymes (e.g. conjugated with antibodies) and the substrates thereof or other substances which are capable of binding antibodies.
  • the L. intracellularis bacteria as disclosed herein or known in the art, or components derived from such bacteria, can be used as an antigen in an ELISA or other immunoassay, such as an immunofluorescent antibody test ("IFA"), to detect antibodies to L. intracellularis in the serum and other body fluids of animals suspected of being infected with the bacteria.
  • IFA immunofluorescent antibody test
  • the presently preferred immunoassay is an IFA as described in the example below.
  • the bacteria of the instant invention can be used in a Western Blot assay.
  • the preferred Western Blot protocol is as follows:
  • the conjugate linked to the antibody could be for example an enzyme, such as a. horse radish peroxidase (HRP) or alkaline phosphatase (AP).
  • HRP horse radish peroxidase
  • AP alkaline phosphatase
  • a chromophore, or any other detectable substance which is can be quantified in the presence of a substrate can be used as conjugate.
  • the most preferred immune test according to the invention is an ELISA.
  • capture ELISA capture ELISA
  • Such an ELISA is more specific, as it detects with two antibodies specific to two different epitopes on the same antigen.
  • unlabelled antibodies are coated to the microtiter plates.
  • the L. intracellularis as antigen is subsequently added.
  • the bound L. intracellularis antigen is detected with a second, labeled, L. intracellularis-specific antibody reactive to a different epitope on L. intracellularis.
  • a preferred ELISA protocol according to the invention is as follows (use of antibody coated plates):
  • a preferred ELISA is carried out as follows:
  • Antigen as used herein is L. intracellularis as defined above.
  • mAb relates to a monoclonal antibody specific for L. intracellularis.
  • such antibody is an antibody as disclosed below.
  • the antibodies have the following reference numbers: 301:39, 287:6, 268:29, 110:9, 113:2 and 268:18. All antibodies are specific for antigens of L. intracellularis bacteria.
  • capture antibodies in a sandwich ELISA are 110:9, 113:2 or 287:6, and as conjugated antibodies 268:18, 268:29 or 287:6.
  • capture antibody 110:9 and as conjugated antibody is antibody 268:29.
  • antibodies having all of characteristics of such antibodies mentioned above, which means having nearly the same binding characteristics of the antibodies mentioned above, and/or which are directed to the same antigens of Lawsonia intracellularis as compared to the antibodies mentioned above, and/or are directed to or identifying the same epitopes as compared to those antibodies mentioned above.
  • the antibodies according to the invention are produced by hybridoma cells. Said hybridoma cells according to the invention are deposited at the Centre for Applied Microbiology and Research (CAMR) and European Collection of Cell Cultures (ECACC), Salisbury, Wiltshire SP4 OJG, UK, as patent deposit according to the Budapest Treaty. The date of deposit was May 11, 2004.
  • HYBRIDOMA CELL LINE 110:9 is successfully deposited under ECACC Acc. No. 04092204.
  • HYBRIDOMA CELL LINE 113:2 is successfully deposited under ECACC Acc. No. 04092201.
  • HYBRIDOMA CELL LINE 268:18 is successfully deposited under ECACC Acc. No. 04092202.
  • HYBRIDOMA CELL LINE 268:29 is successfully deposited under ECACC Acc. No. 04092206.
  • HYBRIDOMA CELL LINE 287:6 is successfully deposited under ECACC Acc. No. 04092203.
  • HYBRIDOMA CELL LINE 301:39 is successfully deposited under ECACC Acc. No. 04092205.
  • anti-Lawsonia hybridomal celline 372:13, 113:2, 268:18, 287:6, 110:9, 268:29, 301:39.
  • the preparation of the monoclonal antibodies was performed according to standard operating procedures at Svanova Biotech.
  • the purified and HRP conjugated mAb's were tested for their ability to be blocked by positive Lawsonia pig sera in ELISA.
  • the ELISA was performed according to the following procedure:
  • Capture mAb 110:9, 113:2 and 287:6 with conjugates 268:18 and 268:29 and 287:6 seems to be the best candidates for the sandwich B-ELISA as these combinations showed the best blocking capacity on the positive sera. Sera no #6 scored positive in most of the tests. This was suspected as this sera also scored positive in the previously developed B-ELISA prototype.
  • the capture mAb 110:9 was found to be the best choice as it gave the clearest differentiation between positive and negative samples.
  • the performed accelerated stability studies indicate that the Lawsonia intracellularis antigen captured ELISA plate has a stability of at least one year and that the a- Lawsonia HRP conjugate 268:29 has a stability of 6 to 12 months in a lyophilized form.
  • Plates were coated with Lawsonia mAb 110:9 blocked with 10% Sucrose /10% Normal Horse serum in ddH 2 O and incubated with Lawsonia antigen. Plates were dried and sealed and put in +37°C. Plates were taken from +37C weeks 1, 2, 3 and 4 and stored in a refrigerator. Plates were also stored in +4C for the whole test-period as a reference.
  • HRP conjugated mAb 268:29 lot #030120 was diluted 1/1000 in CDS-C buffer dispensed into glass bottles and lyophilized according to standard procedures. Four lyophilized bottles were stored at +37C for 1, 2, 3 and 4 weeks. Bottles were also stored at 4C. The different bottles were tested in the sandwich ELISA.
  • conjugated antibody was therefore titrated in the plate to obtain a correct signal for the test.
  • the performed accelerated stability studies indicate that the Lawsonia intracellularis ELISA plate has a stability of at least one year.
  • the anti-Lawsonia HRP conjugated 268:29 antibody showed a 40% decrease in OD value against the negative sera and after 4 weeks. This might indicate some instability of the conjugate.
  • a 40% decrease of a signal at 1.5 means and OD value of 0.9 after 1 year which is still within the acceptance criteria.
  • the verification of the prototype was performed by testing 50 sera previously used when developing the prototype.
  • the verification study showed a 100% agreement with the positive sera while 2 of the 25 negative sera scored positive in the verified batch.
  • Buffer CDS-C is used as preservative when lyophilizing the HRP conjugate. This buffer contains swine sera. As it can be problematic in the future to find Lawsonia negative sera to be used in the CDS-C buffer an alternative has to be tested. In this study normal horse serum and foetal bovine serum were tested.
  • CDS-C buffer was prepared with; 1- swine serum (as in TJ4/05F), 2- with normal horse serum and 3- with foetal bovine serum.
  • the buffers were tested as conjugate buffer in the ELISA. Serum tested were gris 2, 4, 13 and 17, 1-29664, 3-29664, A-27239, B-27239, #26 and C2.
  • HRP conjugated mAb 268:29 lot #030318 was used.
  • 20 x conc PBST with 0.042% PVP was used
  • CDS-C buffer containing normal horse serum has been used to prepare lyophilized conjugate at two occasions (040211, 040308).
  • the conjugate was prepared to obtain a final dilution of 1/20k, 1/25k and 1/30k. Freshly prepared conjugate was tested in parallel. Serum #26, 1-29664, 3-29664, A-27239, B-27239, pos pool 030926 and neg pool 030926 were used. HRP conjugated mAb 268:29 lot#030318 was used. 20 x conc PBST with 0.042% PVP was used.
  • PBST buffer 20x concentrated was diluted 1/20 and a final concentration of 0.042% PVP was added. This buffer was tested in parallel with PBST tablets (already containing PVP) and 20x conc PBST buffer diluted 1/20. The buffers were used in all steps, i.e. in the sample and conjugate dilution buffer as well as in the washing buffer.
  • Serum #26, E1, 1-29664, 3-29664, A-27239, B-27239 and gris 13 were used.
  • HRP conjugated mAb 268:29 lot #030318 was used.
  • conjugate buffer CDS-C with swine serum was used.
  • the buffer containing normal horse serum showed similar results as the one with swine sera.
  • L. intracellularis antigen grown on a McCoy cell culture and captured by a specific monoclonal antibody on microtiter plates was used to detect antibodies against L. intracellularis in porcine serum samples.
  • Sera were tested in a 1 to 10 dilution. After 1 h of incubation at 37 °C plates were washed with PBS Tween solution, horseradish-peroxidase labeled monoclonal antibody (different to the capture antibody) was added. The plates were incubated for an additional hour at 37 °C. Unbound antibodies were removed by washing. After incubation with TMB substrate for 10 min at room temperature the reaction was stopped by adding a stop solution. The OD 450 was read in a photometer for each well. Results were calculated as percent inhibition of controls without serum.
  • Results from the 301 field sera are summarized in Figure 2 .
  • the ELISA clearly discriminates between negative (mean relative ELISA value 36) and positive sera (mean relative ELISA value 89). Majority of the samples that scored doubtful in the IFA were positive in the ELISA.
  • the ELISA provides a higher sensitivity. In some groups of the 3 tested farms the result from the ELISA is much more unambiguous than in the IFA test, that gave a lot of questionable results, due to unspecific fluorescence.
  • the serological profiles in the 3 herds corresponded well to previously published data from European herds (3,4). The increase of ELISA values between the group of 10 and 16 weeks old pigs in comparison to the IFA test results indicate, that sera with relative ELISA values greater 55 can be judged as positive.
  • the new blocking Ileitis ELISA provides a tool for fast and sensitive screening of large amounts of samples on an objective basis.
  • IFA tests for antibody detection (1,2) or PCR (3,4), histological and immuno-staining methods (2,5,6) for antigen detection in feces or intestinal tissue samples. All these methods have specific disadvantages concerning specificity, contamination risk or workload and are not suitable for routine herd screenings on a large scale. So most diagnostic tests are done only for few pigs from a herd. By the use of a recently developed blocking ELISA serological testing becomes easier, more reliable and suitable for herd profiling. Cross-sectional screenings of 22 farms in Germany were performed to demonstrate the diagnostic performance of the new test.
  • the new ELISA according to the invention provides a powerful tool for serological diagnosis of Ileitis suitable for routine testing of large sample sizes and cross-sectional herd screenings.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (9)

  1. Verfahren zur Diagnose einer präklinischen oder klinischen Lawsonia intracellularis-Infektion, umfassend die folgenden Schritte:
    a) Nachweis der spezifischen Bindung einer flüssigen Probe an einen L. intracellularis-Antikörper, wobei die Antikörper ausgewählt sind aus der Gruppe bestehend aus monoklonalem Antikörper 301:39, erhalten aus der Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092205, monoklonalem Antikörper 287:6, erhalten aus der Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092203, monoklonalem Antikörper 268:29, erhalten aus der Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092206, monoklonalem Antikörper 110:9, erhalten aus der Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092204, monoklonalem Antikörper 113:2, erhalten aus der Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092201 und monoklonalem Antikörper 268:18, erhalten aus der Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092202,
    b) Vergleich des in a) erhaltenen Ergebnisses mit einer Kontrolle.
  2. Verfahren nach Anspruch 1, worin das Verfahren ein Immuntest ist.
  3. Verfahren nach Anspruch 1 oder 2, worin die Methode ein ELISA ist.
  4. Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092204, welche Antikörper 110:9 sekretiert.
  5. Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092201, welche Antikörper 113:2 sekretiert.
  6. Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092202, welche Antikörper 268:18 sekretiert.
  7. Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092206, welche Antikörper 268:29 sekretiert.
  8. Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092203, welche Antikörper 287:6 sekretiert.
  9. Hybridom-Zelllinie ECACC Hinterlegungsnummer 04092205, welche Antikörper 301:39 sekretiert.
EP05755345A 2004-06-24 2005-06-23 Verfahren zur diagnose von lawsonia intracellularis Active EP1761785B1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL05755345T PL1761785T3 (pl) 2004-06-24 2005-06-23 Sposób diagnozowania Lawsonia intracellulari
EP05755345A EP1761785B1 (de) 2004-06-24 2005-06-23 Verfahren zur diagnose von lawsonia intracellularis
SI200531153T SI1761785T1 (sl) 2004-06-24 2005-06-23 Postopek za diagnosticiranje Lawsonie intracellularis
CY20101101071T CY1110948T1 (el) 2004-06-24 2010-11-24 Μεθοδος διαγνωσης lawsonia intracellularis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04014804A EP1609870A1 (de) 2004-06-24 2004-06-24 Methode, um Lawsonia intracellularis zu diagnostizieren
EP04027193 2004-11-16
EP05755345A EP1761785B1 (de) 2004-06-24 2005-06-23 Verfahren zur diagnose von lawsonia intracellularis
PCT/EP2005/006781 WO2006012949A1 (en) 2004-06-24 2005-06-23 Method of diagnosing lawsonia intracellularis

Publications (2)

Publication Number Publication Date
EP1761785A1 EP1761785A1 (de) 2007-03-14
EP1761785B1 true EP1761785B1 (de) 2010-08-25

Family

ID=34971368

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05755345A Active EP1761785B1 (de) 2004-06-24 2005-06-23 Verfahren zur diagnose von lawsonia intracellularis

Country Status (21)

Country Link
US (12) US7303891B2 (de)
EP (1) EP1761785B1 (de)
JP (1) JP2008503737A (de)
KR (2) KR101306610B1 (de)
CN (1) CN1973205B (de)
AR (1) AR049411A1 (de)
AT (1) ATE479100T1 (de)
AU (1) AU2005269043B2 (de)
BR (1) BRPI0512546B1 (de)
CA (1) CA2568821C (de)
CY (1) CY1110948T1 (de)
DE (1) DE602005023157D1 (de)
DK (1) DK1761785T3 (de)
MX (1) MXPA06015207A (de)
MY (1) MY146476A (de)
PL (1) PL1761785T3 (de)
PT (1) PT1761785E (de)
RU (1) RU2400758C2 (de)
SI (1) SI1761785T1 (de)
TW (1) TW200617174A (de)
WO (1) WO2006012949A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY146476A (en) * 2004-06-24 2012-08-15 Boehringer Ingelheim Vetmed Method of diagnosing lawsonia intracellularis
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US8398994B2 (en) 2005-07-15 2013-03-19 Boehringer Ingelheim Vetmedica, Inc. Lawsonia vaccine and methods of use thereof
US20080241190A1 (en) * 2006-11-13 2008-10-02 Boehringer Ingelheim Vetmedica, Inc. Vaccination of horses against lawsonia intracellularis
EP2101815A4 (de) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Wirksames verfahren zur behandlung von infektionen mit porcinem circovirus und lawsonia intracellularis
US8398970B2 (en) * 2007-09-17 2013-03-19 Boehringer Ingelheim Vetmedica, Inc. Method of preventing early Lawsonia intracellularis infections
US10125388B2 (en) 2007-10-31 2018-11-13 Akonni Biosystems, Inc. Integrated sample processing system
WO2010010055A1 (en) * 2008-07-22 2010-01-28 Intervet International B.V. Lawsonia intracellularis bacterium of a novel serotype, vaccine based on that bacterium, antibodies suitable for diagnosing the novel lawsonia intracellularis serotype and hybridomas for producing the said antibodies
US8518658B1 (en) * 2009-04-27 2013-08-27 University Of South Florida ATP-bioluminescence immunoassay
CN105969761B (zh) * 2009-09-21 2020-04-07 阿科尼生物系统公司 磁力裂解方法和装置
EP2523434A1 (de) 2011-05-11 2012-11-14 10n2 Technologies, Inc. Verfahren zur Einschränkung der Verwendung einer mobilen Kommunikationsvorrichtung abhängig der Bewegungsgeschwindigkeit
CN103698514B (zh) * 2013-12-17 2015-11-18 广西大学 检测猪胞内劳森氏菌抗体的elisa试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130232A (en) * 1990-06-12 1992-07-14 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibody immunoassay kit for avian reticuloendotheliosis virus
JP3547022B2 (ja) * 1994-12-16 2004-07-28 富士写真フイルム株式会社 磁気記録媒体
US5714375A (en) 1995-06-05 1998-02-03 Nobl Laboratories, Inc. Ileal symbiont intracellularis propagation in suspended host cells
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
WO1997020050A1 (en) 1995-11-30 1997-06-05 Daratech Pty. Ltd. Therapeutic and diagnostic compositions
EP0974660A1 (de) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle-Krankheitsvirus Infektiöser Klone, Impfstoffe und Diagnosetest
CN1260492A (zh) * 1999-11-09 2000-07-19 赵永同 肿瘤预后评估试剂盒及其制备工艺
JP2004529854A (ja) 2000-09-29 2004-09-30 アリゾナ・ボード・オブ・リージエンツ・オン・ビハーフ・オブ・ザ・ユニバーシテイー・オブ・アリゾナ 増殖性回腸炎のための改善されたワクチン及びその作製と使用の方法
EP1219711B1 (de) 2000-12-20 2006-06-14 Intervet International BV Lawsonia intracellularis Impfstoff
JP4079727B2 (ja) 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
EP1570045A4 (de) 2002-10-04 2007-09-05 Univ Minnesota Nukleinsäure- und polypeptidsequenzen aus lawsonia intracellularis sowie verwendungsverfahren
WO2005070958A2 (en) 2004-01-22 2005-08-04 Intervet International B.V Lawsonia intracellularis subunit vaccines
MY146476A (en) * 2004-06-24 2012-08-15 Boehringer Ingelheim Vetmed Method of diagnosing lawsonia intracellularis

Also Published As

Publication number Publication date
US20110201788A1 (en) 2011-08-18
US20110275147A1 (en) 2011-11-10
US8007801B1 (en) 2011-08-30
US7635590B2 (en) 2009-12-22
US8058062B1 (en) 2011-11-15
BRPI0512546B1 (pt) 2016-07-19
DE602005023157D1 (de) 2010-10-07
PT1761785E (pt) 2010-11-10
EP1761785A1 (de) 2007-03-14
US7303891B2 (en) 2007-12-04
MY146476A (en) 2012-08-15
US20110275148A1 (en) 2011-11-10
US8003107B1 (en) 2011-08-23
US8021663B2 (en) 2011-09-20
US7993649B1 (en) 2011-08-09
US20110275149A1 (en) 2011-11-10
AU2005269043A1 (en) 2006-02-09
KR101306610B1 (ko) 2013-09-11
CA2568821C (en) 2017-02-14
PL1761785T3 (pl) 2011-02-28
MXPA06015207A (es) 2007-03-26
WO2006012949A1 (en) 2006-02-09
US20070003991A1 (en) 2007-01-04
TW200617174A (en) 2006-06-01
US20110201786A1 (en) 2011-08-18
US8114667B2 (en) 2012-02-14
US20080102479A1 (en) 2008-05-01
US7960174B2 (en) 2011-06-14
SI1761785T1 (sl) 2010-12-31
US20110033870A1 (en) 2011-02-10
DK1761785T3 (da) 2010-11-08
RU2007102426A (ru) 2008-07-27
KR101389302B1 (ko) 2014-04-25
KR20070026855A (ko) 2007-03-08
CN1973205A (zh) 2007-05-30
US20110201789A1 (en) 2011-08-18
US8007802B1 (en) 2011-08-30
BRPI0512546A (pt) 2008-03-25
AU2005269043B2 (en) 2011-10-27
US20110201790A1 (en) 2011-08-18
US7799562B2 (en) 2010-09-21
CY1110948T1 (el) 2015-06-10
JP2008503737A (ja) 2008-02-07
KR20130012085A (ko) 2013-01-31
US20110201787A1 (en) 2011-08-18
US20100112608A1 (en) 2010-05-06
CA2568821A1 (en) 2006-02-09
ATE479100T1 (de) 2010-09-15
AR049411A1 (es) 2006-07-26
CN1973205B (zh) 2012-07-18
RU2400758C2 (ru) 2010-09-27
US8114666B2 (en) 2012-02-14

Similar Documents

Publication Publication Date Title
EP1761785B1 (de) Verfahren zur diagnose von lawsonia intracellularis
CA2222643C (en) Lawsonia intracellularis cultivation, anti-lawsonia intracellularis vaccines and diagnostic agents
Adams et al. Development and use of monoclonal antibody probes forimmunohistochemistry, ELISA and IFAT to detect bacterial and parasitic fish pathogens
US5714375A (en) Ileal symbiont intracellularis propagation in suspended host cells
ES2351511T3 (es) Método de diagnóstico de lawsonia intracellularis.
MXPA97009464A (en) Culture of lawsonia intracellularis, vaccines against lawsonia intracellulares and agents of diagnost

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: BA LV

RAX Requested extension states of the european patent have changed

Extension state: BA

Payment date: 20070124

Extension state: LV

Payment date: 20070124

17Q First examination report despatched

Effective date: 20080508

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: BA LV

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005023157

Country of ref document: DE

Date of ref document: 20101007

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20101102

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20100402548

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Effective date: 20110126

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 8285

Country of ref document: SK

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E009352

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20110621

Year of fee payment: 7

Ref country code: LT

Payment date: 20110520

Year of fee payment: 7

Ref country code: TR

Payment date: 20110520

Year of fee payment: 7

Ref country code: PT

Payment date: 20110620

Year of fee payment: 7

Ref country code: SE

Payment date: 20110613

Year of fee payment: 7

Ref country code: MC

Payment date: 20110613

Year of fee payment: 7

Ref country code: IS

Payment date: 20110519

Year of fee payment: 7

Ref country code: GR

Payment date: 20110624

Year of fee payment: 7

Ref country code: IE

Payment date: 20110621

Year of fee payment: 7

26N No opposition filed

Effective date: 20110526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20110621

Year of fee payment: 7

Ref country code: SI

Payment date: 20110527

Year of fee payment: 7

Ref country code: RO

Payment date: 20110530

Year of fee payment: 7

Ref country code: PL

Payment date: 20110617

Year of fee payment: 7

Ref country code: FI

Payment date: 20110613

Year of fee payment: 7

Ref country code: EE

Payment date: 20110614

Year of fee payment: 7

Ref country code: AT

Payment date: 20110613

Year of fee payment: 7

Ref country code: BG

Payment date: 20110613

Year of fee payment: 7

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005023157

Country of ref document: DE

Effective date: 20110526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20110705

Year of fee payment: 7

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20121226

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20120623

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120623

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121231

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120623

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120623

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120630

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120623

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E004970

Country of ref document: EE

Effective date: 20120630

Ref country code: AT

Ref legal event code: MM01

Ref document number: 479100

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121226

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120624

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20130125

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 8285

Country of ref document: SK

Effective date: 20120623

Ref country code: GR

Ref legal event code: ML

Ref document number: 20100402548

Country of ref document: GR

Effective date: 20130104

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120623

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120623

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120630

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130104

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120624

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120623

REG Reference to a national code

Ref country code: PL

Ref legal event code: LAPE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120630

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230828

Year of fee payment: 19

Ref country code: CH

Payment date: 20230702

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240619

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240619

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240621

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240619

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240619

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240628

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240619

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240625

Year of fee payment: 20